IRVINE, CA, and HERSTAL, BELGIUM – October 4, 2016 – MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, today announced that it has signed a distribution agreement for their SelectMDx(TM) for Prostate Cancer assay in select countries in Central and South America with SouthGenetics Inc.
Under the terms of the agreement SouthGenetics, a biotechnology distribution company based in Montevideo, Uruguay, will have the rights to distribute SelectMDx assay within the following countries: Argentina, Bolivia, Chili, Columbia, Ecuador, Mexico, Peru, Dominican Republic, Panama, Paraguay, Uruguay, and Venezuela.
“MDxHealth is pleased to have this opportunity to provide SelectMDx testing for patients throughout Latin America through this collaborative agreement with SouthGenetics,” stated Dr. Jan Groen, CEO of MDxHealth. “Helping to improve both the quality of care and outcomes for those suspected of harboring prostate cancer throughout Latin America.”
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive ‘liquid biopsy’ method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.
SouthGenetics is a biotechnology distribution company with presence in major Latin American countries including; Argentina, Colombia, Chile, Dominican Rep, Ecuador, Mexico, Panama, Paraguay, Peru and Venezuela. The company’s mission is to provide patients and doctors access to the highest quality emerging diagnostics tools available. Through strategic partnerships it provides high quality diagnostic services in many clinical areas, such us oncology, gynecology and urology. For more information visit: www.southgenetics.com
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Jonathan Birt, Chris Welsh, Hendrik Thys, Cameron Standage (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.